CN102327587B - Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation - Google Patents
Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation Download PDFInfo
- Publication number
- CN102327587B CN102327587B CN2011102893252A CN201110289325A CN102327587B CN 102327587 B CN102327587 B CN 102327587B CN 2011102893252 A CN2011102893252 A CN 2011102893252A CN 201110289325 A CN201110289325 A CN 201110289325A CN 102327587 B CN102327587 B CN 102327587B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- chinese medicine
- rhizoma
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and a preparation method of Chinese medicine preparation. The Chinese herbal medicine consists of the following raw materials by weight: 1 to 100 parts of radix pseudostellariae, 1 to 98 parts of fried atractylodes, 1 to 100 parts of glabrous greenbrier rhizome, 1 to 98 parts of baked licorice, 1 to 98 parts of cinnamon twig, 1 to 98 parts of radix paeoniae alba, 1 to 98 parts of cynomorium, 1 to 98 parts of epimedium, 1 to 98 parts of poison yam, 1 to 98 parts of dioscorea, 1 to 98 parts of flos lonicerae, 1 to 98 parts of herba taraxaci, 1 to 98 parts of ginger and 1 to 98 parts of jujube. The preparation method of the Chinese medicine preparation comprises the following steps that: (1) weighing the raw materials according to the compositions of the Chinese herbal medicine; and (2) placing the raw materials into a pot, filling water into the pot to immerse the herbs, starting steam to steam the herbs for two times, filtering the medicine lotion, and mixing the filtered medicine lotion. Due to the adoption of the Chinese herbal medicine, the efficacy on clinically curing chronic immune thrombocytopenia (cITP) patients or intractable immune thrombocytopenia (rITP) patients can be improved, and the abnormal immune state of the cITP patients or rITP patients can be effectively adjusted.
Description
Technical field
The present invention relates to a kind of Chinese medicine and Chinese medicine preparation preparation method that is used for the treatment of chronic or intractable immune thrombocytopenia.
Background technology
Thrombocytopenia former " idiopathic thrombocytopenic purpura (Idiopathic thrombocytopenic purpura, ITP) " by name, ITP is a kind of acquired autoimmune disease, is the thrombocytopenia caused by immunologic function disorder; Can think that ITP is a kind of " autoimmune disease ", cause that the definite mechanism of ITP it be unclear that.International (the International Working Group of working group of ITP in 2007, IWG) recommend idiopathic thrombocytopenic purpura is renamed as " immune thrombocytopenia (Immune thrombocytopenia; ITP) ", recommendation " immunity " (Immune), with emphasize the morbidity by immune-mediated; In addition, because quite a few patient does not have or the slight bleeding symptom is only arranged, no longer use " purpura " (purpura); ITP is still write in abbreviation.According to ITP clinical manifestation, thrombocytopenic persistent period and therapeutic effect, domestic haematologist reached Consensus of experts in 2009, and the adult idiopathic thrombocytopenic purpura is divided into to the ITP (ndITP) of new diagnosis-diagnosed within 3 months, continues ITP (pITP)-3-12 month, chronic ITP (cITP)-continue more than 12 months and intractable ITP (rITP) fourth phase or four types.
CTIP is mainly in the adult, insidious onset, and except finding that thrombocytopenia, self-induction are weak, but non-evident sympton and sign, the existing platelet count of multilist is difficult to maintain normal physiological level, Relapse rate and is easy to the characteristics such as recurrence.The cTIP some cases shows as intractable, is embodied in: (1) splenectomy invalid or the recurrence; (2) need (comprising low dose of adrenocortical hormone and other treatments) treatment to reduce hemorrhage risk; (3) ITP diagnosis is clear and definite, except other cause thrombocytopenic reason.The domestic clinical characters that goes up according to this is attributed to refractory idiopathic thrombocytopenic purpura (refractory Immune thrombocytopeniarITP) by this type of case.
The first-selected bran 17-hydroxy-11-dehydrocorticosterone of western medicine ITP, but side effect is more.Treatment by Chinese herbs ITP has advantages of that side effect is little, but prolonged application and non-evident effect; And the ITP patient that can not alleviate for Western medicine, Chinese medicine still has curative effect preferably.But the ITP of Chinese medicine treatment at present exists following technological deficiency: 1, clinical efficacy is remarkable not: it is obvious not that platelet promotes quantity, and ITP patient's effective percentage is lower; 2, can not effectively regulate ITP patient's abnormal immune state and make the immune state of ITP patient's disorder be tending towards normal; 3, the curative effect for cITP patient or rITP patient is not remarkable.
Summary of the invention
For the deficiencies in the prior art, the object of the present invention is to provide a kind of Chinese medicine and Chinese medicine preparation preparation method that is used for the treatment of chronic or intractable immune thrombocytopenia, improve clinical treatment cITP patient or rITP patient's effective percentage, and effectively regulate cITP patient or rITP patient's abnormal immune state and make the immune state of cITP patient or rITP patient's disorder be tending towards normal.
Technical scheme of the present invention is achieved in that a kind of Chinese medicine that is used for the treatment of chronic or intractable immune thrombocytopenia, raw material by following portions by weight forms: 1 part～100 parts of Radix Pseudostellariaes, 1 part～98 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 1 part～100 parts of Rhizoma Smilacis Glabraes, 1 part～98 parts of Radix Glycyrrhizae Preparatas, 1 part～98 parts of Ramulus Cinnamomi, 1 part～98 parts of the Radix Paeoniae Albas, 1 part～98 parts of Herba Cynomoriis, 1 part～98 parts of Herba Epimedii, 1 part～98 parts of Chuan Rhizoma Dioscoreae Septemlobae, 1 part～98 parts of Rhizoma Dioscoreae Nipponicae, 1 part～98 parts of Flos Loniceraes, 1 part～98 parts of Herba Taraxaci, 1 part～98 parts, 1 part～98 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.
The Chinese medicine that is used for the treatment of chronic or intractable immune thrombocytopenia, 5 parts～100 parts of Radix Pseudostellariaes, 5 parts～50 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 5 parts～100 parts of Rhizoma Smilacis Glabraes, 5 parts～50 parts of Radix Glycyrrhizae Preparatas, 5 parts～50 parts of Ramulus Cinnamomi, 5 parts～50 parts of the Radix Paeoniae Albas, 5 parts～80 parts of Herba Cynomoriis, 5 parts～80 parts of Herba Epimedii, 5 parts～80 parts of Chuan Rhizoma Dioscoreae Septemlobae, 5 parts～100 parts of Rhizoma Dioscoreae Nipponicae, 5 parts～80 parts of Flos Loniceraes, 5 parts～100 parts of Herba Taraxaci, 5 parts～80 parts, 5 parts～80 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.
The Chinese medicine that is used for the treatment of chronic or intractable immune thrombocytopenia, 30 parts of crown princes, 10 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 30 parts of Rhizoma Smilacis Glabraes, 10 parts of Radix Glycyrrhizae Preparatas, 10 parts of Ramulus Cinnamomi, 10 parts of the Radix Paeoniae Albas, 20 parts of Herba Cynomoriis, 10 parts of Herba Epimedii, 20 parts of Chuan Rhizoma Dioscoreae Septemlobae, 30 parts of Rhizoma Dioscoreae Nipponicae, 20 parts of Flos Loniceraes, 30 parts of Herba Taraxaci, 30 parts, 10 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.
Utilize the Chinese medicine preparation preparation method of above-mentioned Chinese medicine, (1) forms and takes respectively raw material by described Chinese medicine; The raw material that (2) will take drops into steaming and decocting and extracts in pot, adds water logging and crosses medical material, opens vapour cooking twice, filters merging filtrate.
Above-mentioned Chinese medicine preparation preparation method, while also comprising the steps: that (3) are concentrated into 60 ℃ by filtrate, relative density is 1.09～1.12, be cooled to room temperature, add ethanol, stir, the standing precipitation that makes more than 12 hours is complete, gets supernatant, reclaim ethanol, while being concentrated into 60 ℃, relative density is 1.30～1.33 extractum; (4) add adjuvant, make corresponding dosage form by the preparation technology of required dosage form.
Above-mentioned Chinese medicine preparation preparation method, described dosage form is for having sugared granule, sugar free granule type, tablet, capsule, powder, unguentum, oral liquid, syrup, electuary, mixture, buccal tablet or effervescent tablet.According to different dosage forms, also can adopt said method traditional extracting method in addition extract and prepare.
Above-mentioned Chinese medicine preparation preparation method, described adjuvant are one or more in binding agent, filler, correctives and wetting agent.
The invention has the beneficial effects as follows: in side, Radix Pseudostellariae is monarch drug, and Siberian cocklebur Rhizoma Atractylodis Macrocephalae grass is joined in invigorating the spleen and benefiting QI, gets four gentleman's meaning invigorating the spleen and benefiting QI, turns round and look at the deficiency of vital energy originally; Herba Cynomorii, the Herba Epimedii kidney tonifying is supporing yang, and facilitating fire for tonifying the spleen is ministerial drug; The guizhi decoction harmonizing yingfen and weifen, Gu protects lung and defends as assistant, disturbs as making on river Rhizoma Dioscoreae Septemlobae, Rhizoma Dioscoreae Nipponicae, Flos Lonicerae, Herba Taraxaci solution ailment said due to cold or exposure, and guizhi decoction had both helped the absorption of purpura, also was conducive to resist the diseases caused by exogenous pathogenic factor pathogenic heat and invaded and harassed, the merit of killing two birds with one stone.
The present invention is applied in cITP patient or rITP patient's clinical treatment: platelet promote quantity obviously, cITP patient or rITP patient's effective percentage is high, evident in efficacy; Can effectively regulate cITP patient or rITP patient's abnormal immune state and make the immune state of cITP patient or rITP patient's disorder be tending towards normal.
The specific embodiment
For further objective evaluation effect of the present invention, 58 routine clinical trials have been carried out by China TCM Academy of Sciences Xiyuan Hospital hematology (Ministry of Public Health whole nation traditional Chinese medical science hematopathy Pivot Subjects, State Administration of Traditional Chinese Medicine's traditional Chinese medical science hematopathy key discipline, three grades of laboratorys of State Administration of Traditional Chinese Medicine's Chinese medicine science and technology).
1. research approach
1.1 diagnostic criteria
The Western medicine diagnose standard: the diagnostic criteria of the reference middle idiopathic thrombocytopenic purpura (idiopathic thrombocytopenic purpura, ITP) of formulating of Zhang Zhinan chief editor " diagnosis of hematological diseases and criterion of therapeutical effect " in 2007: (1) many experiments chamber checks the platelet count minimizing; (2) not enlargement of spleen or slight the increase; (3) bone marrow examination megalokaryocyte number increases or normally, dysmaturity is arranged; (4) should have wherein one in following 5: (a) Prednisone Therapy is effective; (b) cut spleen effective; (c) PAIgG increases; (d) PAC3 increases; (e) platelet life span shortens; (5) get rid of secondary thrombocytopenia.
TCM syndrome diagnostic criteria: with reference in August, 1987 whole nation tcm emergency seminar revision scheme, draft in conjunction with 2002 " new Chinese medicine guideline of clinical investigations ".Asthenia of both the spleen and kidney card is dialectical with reference to yang deficiency of spleen and stomache and deficiency of qi and blood type syndrome standard: 1. primary symptom: substantially without hemorrhage syndrome, or the purpura color is light red or dark and sparse, accompanies refreshing tired weak, especially weak obviously with two lower limb, or aversion to cold and cold limbs, soreness of the waist and knees, desire for hot drinks, diarrhea with loose stool, polyuria; 2. time disease: dizziness, cardiopalmus, breathe hard, Diarrhoea.Picture of the tongue: light red tongue or light fat, or indented tongue margin, white and thin fur; Pulse condition: deep-slow pulse or weak pulse.The tool primary symptom is more than 2; Or 1 primary symptom adds 1 with disease last time, then it is namely diagnosable to add the tongue pulse condition.
1.2 case inclusion criteria: (1) meets chronic ITP diagnostic criteria, the course of disease>12 month; (2) the be separated by average platelet counting<50 * 10 of continuous 2 times of all left and right
9/ L, and do not take hormone or prednisone dose≤10mg; (3) meet traditional Chinese medical science spleen kidney both deficiency type differentiation of symptoms and signs for classification of syndrome; (4) age is between 10～75 years old; (5) do not participate in other clinical researches, tested voluntarily.
1.3 case exclusion standard: (1) secondary thrombocytopenic purpura, as high as various autoimmune diseasees, Drug, MDS or spleen etc. due to thrombocytopenia; (2) do not meet the inclusive criteria person of clinical research scheme regulation; (3) merge severe cardiac, brain, liver, kidney disease and psychotic; (4) gestation, women breast-feeding their children or allergic constitution person; (5) participate in other clinical researches.
1.4 reject the case standard: (1) due to subjectivity or odjective cause, not medication in accordance with regulations, or data not umbra rings efficacy determination; (2) include the rear discovery person that do not meet the inclusion criteria in.
2. research method
2.1 case is selected
Object of study is China TCM Academy of Sciences Xiyuan Hospital clinic case between year October in June, 2006 to 2010, is diagnosed as ITP by inspections such as routine blood test, bone marrow smear, platelet antibody, antinuclear antibody and B ultrasonic, and the course of disease, more than 1 year, can be examined as cITP.Zhang Zhinan chief editor " diagnosis of hematological diseases and criterion of therapeutical effect " is adopted in diagnostic criteria.By the consulting hours order, enter group, totally 58 examples.
2.2 medicine
Chinese medicine preparation preparation method of the present invention comprises the steps: that (1) forms and takes respectively raw material by weight: 30 parts of crown princes, 10 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 30 parts of Rhizoma Smilacis Glabraes, 10 parts of Radix Glycyrrhizae Preparatas, 10 parts of Ramulus Cinnamomi, 10 parts of the Radix Paeoniae Albas, 20 parts of Herba Cynomoriis, 20 parts of 10 parts of Chuan Rhizoma Dioscoreae Septemlobae of Herba Epimedii, 30 parts of Rhizoma Dioscoreae Nipponicae, 20 parts of Flos Loniceraes, 30 parts of Herba Taraxaci, 30 parts, 10 parts, Rhizoma Zingiberis Recens and Fructus Jujubae; (2) the above-mentioned raw material taken is dropped into to steaming and decocting and extract in pot, add water logging and cross medical material, open vapour cooking twice, filter, after merging filtrate, must treat the decoction of use.
Instructions of taking: decoction potion on the one, sooner or later divide and take for 2 times; The primary crude drug 230 that each decoction of taking in is equivalent in above-mentioned steps (1) after proportioning is by weight restrained the standby decoction obtained.
2.3 observational technique
Treatment group: observed altogether 4 months, the 1st, respectively recorded leukocyte, hemoglobin, platelet count, the TCM Syndrome Theories table of integrals in 2,4 months.Later stage observes: tracing observation 6 months, estimate long-term efficacy and the monitoring state of an illness.
3. observation index
3.1 tcm syndrome integration
The tcm syndrome table of integrals
3.2 peripheral hemogram
Platelet count, numeration of leukocyte and hemoglobin content.The 1st, 2,4 months each records once
4. curative effect judging standard
4.1 doctor trained in Western medicine curative effect judgment criteria
As follows with reference to Zhang Zhinan chief editor " diagnosis of hematological diseases and criterion of therapeutical effect " ITP criterion of therapeutical effect: (1) produce effects: platelet recovery is normal, without bleeding, continues more than 3 months.Maintain more than 2 years and cure for basic without the recidivist.(2) good effect: platelet rises to 50 * 10
9/ L or more former level rise 30 * 10
9More than/L, without or substantially without bleeding, continue more than 2 months.(3) progressive: platelet rises to some extent, and bleeding improves, more than continuing for 2 weeks.(4) invalid: platelet count and bleeding are without improving or worsening.
4.2 tcm syndrome curative effect judgment criteria
Computing formula: [integration before (integration after integration before treatment-treatment)/treatment] * 100%
Clinical recovery: tcm clinical practice symptom, sign disappear fully, and the syndrome integration reduces >=95%.
Produce effects: tcm clinical practice symptom, sign are obviously improved, and the syndrome integration reduces >=70%.
Effectively: tcm clinical practice symptom, sign all take a favorable turn, and the syndrome integration reduces >=30%.
Invalid: tcm clinical practice symptom, sign all are not improved, even increase the weight of, the syndrome integration reduces<30%.
5. statistical analysis
Application SPSS statistics17.0 statistical software carries out statistical analysis, and data are with mean ± standard deviation
Mean, measurement data application t check, the significance of group difference is first used the capable homogeneity test of variance of Levene ' s test, then goes independent sample or paired sample t and check, according to variance together whether, the selection check result; Clinical effective rate enumeration data application x
2Check.Take P<0.05 has significant as difference.
6. result of study
6.1 physical data
Treatment group: object is that between year October in June, 2006 to 2010, the China TCM Academy of Sciences Xiyuan Hospital outpatient service meets into set condition cITP case 58 examples totally, male 17 examples wherein, female's 41 examples, male: female=1: 2.41, age distribution 10～75 years old, the median age 36 years old.
6.2 lanqin oral solutions
6.2.1 patient treatment Platelet change in count
Treatment group is taken Chinese medicine preparation---decoction prepared by Chinese medicine preparation preparation method of the present invention, and 4 months courses for the treatment of, the later stage followed up a case by regular visits to 6 months.Stable disease in observation period, platelet fluctuates 10,000 with the interior Ineffective Cases that is considered as.
Table 1, two groups for the treatment of Platelet means are relatively
(annotate:
*P<0.05, illustrate that the variation for the treatment of group treatment Platelet has significant difference)
Table 1 result shows: the variation for the treatment of Platelet has significant difference (P<0.05).Illustrate that Chinese medicine preparation treatment cITP prepared by Chinese medicine preparation preparation method of the present invention has the significance clinical efficacy.Later stage observed 6 months, in the produce effects case 1 example after 4 months plt be down to 80 * 10
9/ L, fluctuation is 80 * 10 at present
9/ L～90 * 10
9/ L, all the other case stable disease.Uncomfortable untoward reaction does not appear in all cases viewing duration.
6.2.2 clinical total effects research
Table 2, clinical effective rate table (n/%)
Table 2 shows, total case load 58 examples for the treatment of group, produce effects 14 examples (24.14%); Good effect 11 examples (18.97%); Progressive 15 examples (25.86%); Invalid 18 examples (31.03%); 40 examples are always arranged, total effective efficiency 68.97%.Preliminary Clinical Observation also finds, the middle-young patients clinical efficacy is better than the gerontal patient.By the theory of Chinese medical science analysis, although middle-young patients is ill, function is fair, and healthy energy is still sufficient, has certain resistance against diseases, therefore clinical efficacy is better; And the gerontal patient is over fifty, its gas loses certainly, deficiency of vital QI, and function goes down, and resistance against diseases descends, therefore after medicine, rehabilitation duration is longer.
6.2.3 tcm syndrome effectiveness study
Tcm syndrome integration before and after treatment group treatment, through the judgment criteria computing formula: [the front integration of (integration after integration before treatment-treatment)/treatment] * 100% evaluation.Average syndrome integration 16.11 ± 6.79 before treatment; Average syndrome integration 9.18 ± 6.53 after treatment, through the t check, have statistical significance (P<0.05).Illustrate that Chinese medicine of the present invention obviously improves cITP patient's tcm syndrome.Total case load 58 examples, recovery from illness 12 examples (20.69%); Produce effects 14 examples (24.14%); Effective 19 examples (32.76%); Invalid 13 examples (22.41%); Total effective 45 examples (77.59%).Tcm syndrome integration curative effect is in Table 3.
Table 3, treatment group tcm syndrome integration curative effect table
6.2.4 T, bone-marrow-derived lymphocyte subgroup and Th helper T cell subgroup before and after patient's (58 example) treatment:
CITP patient's immune functional state before and after table 4 treatment
Annotate: with Normal group, compare,
*P<0.05,
*P<0.01; With the treatment before compare, △ P<0.05, △ △ P<0.01
We find by upper table, with Normal group, compare the CD3+HLA-DR+ (%) before the treatment of RITP group, CD3+CD25+ (%), CD4+CD45RA+ (%), CD8+CD45RO+ (%), CD8+CD45RA+/RO+, gamma delta T+CD4+ (%), gamma delta T+CD8+ (%), gamma delta T+CD4+/CD8+, V α 24+CD4+ (%), V α 24+CD8+ (%), Th1 (%), Th0 (%) has significant difference (P<0.01, P<0.01, P<0.05, P<0.01, P<0.05, P<0.01, P<0.05, P<0.01, P<0.01, P<0.05, P<0.05, P<0.01, P<0.01), the T sum (%) after the treatment of RITP group, CD3+CD4+ (%), CD3+CD8+ (%), CD4+/CD8+, B sum (%), CD3+CD16+56+ (%), CD45RA (%), CD45RA/RO, gamma delta T+CD4+ (%), gamma delta T+CD4/8, Th2 (%) has significant difference (P<0.01, P<0.01, P<0.05, P<0.01, P<0.05, P<0.05, P<0.05, P<0.01, P<0.01, P<0.01, P<0.05).
Before and after treatment, compare, CD4+/CD8+ (%), CD3+DR+ (%), CD3+CD25+ (%), CD45RA (%), CD45RA/RO, CD4+RA+ (%), CD8+RO+ (%), gamma delta T sum (%), gamma delta T+CD4+ (%), gamma delta T+CD8+ (%), V α 24+CD4+ (%), V α 24+CD8+ (%), Th1 (%), Th0 (%), Th1/Th2 has significant difference (P<0.05, P<0.01, P<0.01, P<0.05, P<0.05, P<0.05, P<0.01, P<0.05, P<0.01, P<0.05, P<0.01, P<0.05, P<0.01, P<0.01, P<0.01, P<0.01).
The RITP group is after the present invention's treatment, CD3+DR+ (%), CD3+CD25+ (%), CD4+RA+ (%), CD8+RO+ (%), gamma delta T sum (%), gamma delta T+CD8+ (%), V α 24+CD4+ (%), V α 24+CD8+ (%), Th1 (%), Th0 (%), Th1/Th2 recover normal, with matched group, compare there was no significant difference, illustrate that the present invention can regulate RITP patient's abnormal immune state significantly, make disorderly immune state be tending towards normal.
After the present invention's treatment, with normal group, compare, T sum (%), CD3+CD8+ (%) be rising (P<0.01 significantly, P<0.01), remarkable (P<0.01, P<0.05 of descending of CD3+CD4+ (%), CD4+/CD8+, B sum (%), CD45RA/RO and gamma delta T+CD4+ (%), P<0.01, P<0.05, P<0.01) also obviously reduce, present the inverted trend of CD4+/CD8+.
Conclusion: in sum, pharmaceutical preparation of the present invention is used for the treatment of cITP, on principle-method-recipe-medicines, is different from supplementing QI and nourishing YIN and clearing away heat and cooling blood method in the past.Studies have shown that, Drug therapy cITP clinical efficacy of the present invention significantly, definitely, significantly promotes Platelet quantity, obviously improves patient's tcm syndrome integration, and late result is reliable and stable, obviously improves patients ' life quality.After Drug therapy of the present invention, patient CD3+DR+ (%), CD3+CD25+ (%), CD4+RA+ (%), CD8+RO+ (%), gamma delta T sum (%), gamma delta T+CD8+ (%), V α 24+CD4+ (%), V α 24+CD8+ (%), Th1 (%), Th0 (%), Th1/Th2 recover, with the treatment before compare significant difference, with Normal group, compare there was no significant difference, illustrate that medicine of the present invention can significantly regulate RITP patient's abnormal immune state, make disorderly immune state be tending towards normal.The present invention is applied to cITP patient or rITP patient's treatment, and curative effect is clear and definite, safe and reliable, saves patient's expense, has higher society generalization and is worth and economic benefit.
In other embodiments, Chinese medicine preparation preparation method of the present invention, in the time of can also comprising the steps: that (3) are concentrated into 60 ℃ by filtrate, relative density is 1.09～1.12, be cooled to room temperature, add ethanol, stir, the standing precipitation that makes more than 12 hours is complete, get supernatant, reclaim ethanol, while being concentrated into 60 ℃, relative density is 1.30～1.33 extractum; (4) add one or more in binding agent, filler, correctives and wetting agent as adjuvant, made sugared granule, sugar free granule type, tablet, capsule, powder, unguentum, oral liquid, syrup, electuary, mixture, buccal tablet or effervescent tablet by the preparation technology of required dosage form; To facilitate clothes for patients, use.
The present invention is used for the treatment of the Chinese medicine of chronic or intractable immune thrombocytopenia, can be formed by the raw material of following portions by weight: 1 part～100 parts of Radix Pseudostellariaes, 1 part～98 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 1 part～100 parts of Rhizoma Smilacis Glabraes, 1 part～98 parts of Radix Glycyrrhizae Preparatas, 1 part～98 parts of Ramulus Cinnamomi, 1 part～98 parts of the Radix Paeoniae Albas, 1 part～98 parts of Herba Cynomoriis, 1 part～98 parts of Herba Epimedii, 1 part～98 parts of Chuan Rhizoma Dioscoreae Septemlobae, 1 part～98 parts of Rhizoma Dioscoreae Nipponicae, 1 part～98 parts of Flos Loniceraes, 1 part～98 parts of Herba Taraxaci, 1 part～98 parts, 1 part～98 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.All can be applied in cITP patient or rITP patient's clinical treatment, make platelet counts lifting, cITP patient or rITP patient's effective percentage high, evident in efficacy; Can effectively regulate cITP patient or rITP patient's abnormal immune state and make the immune state of cITP patient or rITP patient's disorder be tending towards normal.Preferred described Chinese medicine is comprised of the raw material of following parts by weight: 5 parts～100 parts of Radix Pseudostellariaes, 5 parts～50 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 5 parts～100 parts of Rhizoma Smilacis Glabraes, 5 parts～50 parts of Radix Glycyrrhizae Preparatas, 5 parts～50 parts of Ramulus Cinnamomi, 5 parts～50 parts of the Radix Paeoniae Albas, 5 parts～80 parts of Herba Cynomoriis, 5 parts～80 parts of 5 parts～80 parts Chuan Rhizoma Dioscoreae Septemlobae of Herba Epimedii, 5 parts～100 parts of Rhizoma Dioscoreae Nipponicae, 5 parts～80 parts of Flos Loniceraes, 5 parts～100 parts of Herba Taraxaci, 5 parts～80 parts, 5 parts～80 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.More preferred described Chinese medicine is comprised of the raw material of following parts by weight: 30 parts of crown princes, 10 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 30 parts of Rhizoma Smilacis Glabraes, 10 parts of Radix Glycyrrhizae Preparatas, 10 parts of Ramulus Cinnamomi, 10 parts of the Radix Paeoniae Albas, 20 parts of Herba Cynomoriis, 20 parts of 10 parts of Chuan Rhizoma Dioscoreae Septemlobae of Herba Epimedii, 30 parts of Rhizoma Dioscoreae Nipponicae, 20 parts of Flos Loniceraes, 30 parts of Herba Taraxaci, 30 parts, 10 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.Thereby can realize better curative effect.
Claims (6)
1. the Chinese medicine that is used for the treatment of chronic or intractable immune thrombocytopenia, it is characterized in that, raw material by following portions by weight is made: 30 parts～100 parts of Radix Pseudostellariaes, 10 parts～50 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 30 parts～100 parts of Rhizoma Smilacis Glabraes, 10 parts～50 parts of Radix Glycyrrhizae Preparatas, 10 parts～50 parts of Ramulus Cinnamomi, 10 parts～50 parts of the Radix Paeoniae Albas, 20 parts～80 parts of Herba Cynomoriis, 20 parts～80 parts of 10 parts～80 parts Chuan Rhizoma Dioscoreae Septemlobae of Herba Epimedii, 30 parts～100 parts of Rhizoma Dioscoreae Nipponicae, 20 parts～80 parts of Flos Loniceraes, 30 parts～100 parts of Herba Taraxaci, 30 parts～80 parts, 10 parts～80 parts, Rhizoma Zingiberis Recens and Fructus Jujubae.
2. the preparation method of the Chinese medicine preparation of Chinese medicine according to claim 1, it is characterized in that, comprise the steps: that (1) forms and takes respectively raw material by Chinese medicine, Chinese medicine is comprised of the raw material of following portions by weight: 30 parts～100 parts of Radix Pseudostellariaes, 10 parts～50 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 30 parts～100 parts of Rhizoma Smilacis Glabraes, 10 parts～50 parts of Radix Glycyrrhizae Preparatas, 10 parts～50 parts of Ramulus Cinnamomi, 10 parts～50 parts of the Radix Paeoniae Albas, 20 parts～80 parts of Herba Cynomoriis, 10 parts～80 parts of Herba Epimedii, 20 parts～80 parts of Chuan Rhizoma Dioscoreae Septemlobae, 30 parts～100 parts of Rhizoma Dioscoreae Nipponicae, 20 parts～80 parts of Flos Loniceraes, 30 parts～100 parts of Herba Taraxaci, 30 parts～80 parts, 10 parts～80 parts, Rhizoma Zingiberis Recens and Fructus Jujubae, the raw material that (2) will take drops into steaming and decocting and extracts in pot, adds water logging and crosses medical material, opens vapour cooking twice, filters merging filtrate.
3. Chinese medicine preparation preparation method according to claim 2, it is characterized in that, while also comprising the steps: that (3) are concentrated into 60 ℃ by filtrate, relative density is 1.09～1.12, be cooled to room temperature, add ethanol, stir, the standing precipitation that makes more than 12 hours is complete, get supernatant, reclaim ethanol, while being concentrated into 60 ℃, relative density is 1.30～1.33 extractum; (4) add adjuvant, make corresponding dosage form by the preparation technology of required dosage form.
4. Chinese medicine preparation preparation method according to claim 3, is characterized in that, described dosage form is for having sugared granule, sugar free granule type, tablet, capsule, powder, unguentum, oral liquid, syrup, electuary or mixture.
5. Chinese medicine preparation preparation method according to claim 4, is characterized in that, described tablet is buccal tablet or effervescent tablet.
6. Chinese medicine preparation preparation method according to claim 3, is characterized in that, described adjuvant is one or more in binding agent, filler, correctives and wetting agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102893252A CN102327587B (en) | 2011-09-27 | 2011-09-27 | Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102893252A CN102327587B (en) | 2011-09-27 | 2011-09-27 | Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102327587A CN102327587A (en) | 2012-01-25 |
| CN102327587B true CN102327587B (en) | 2013-11-27 |
Family
ID=45479717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102893252A Active CN102327587B (en) | 2011-09-27 | 2011-09-27 | Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327587B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727843B (en) * | 2012-05-31 | 2014-07-02 | 固镇县中医院 | Traditional Chinese medicine for treating thrombocytopenia through invigorating spleen |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686510A (en) * | 2005-04-14 | 2005-10-26 | 赵宏伟 | Ready prepared Chinese medicine for preventing and treating brain apoplexia |
| CN101254275A (en) * | 2008-03-10 | 2008-09-03 | 屈凤星 | Chinese medicine for curing aplastic anemia |
-
2011
- 2011-09-27 CN CN2011102893252A patent/CN102327587B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686510A (en) * | 2005-04-14 | 2005-10-26 | 赵宏伟 | Ready prepared Chinese medicine for preventing and treating brain apoplexia |
| CN101254275A (en) * | 2008-03-10 | 2008-09-03 | 屈凤星 | Chinese medicine for curing aplastic anemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102327587A (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100493597C (en) | Medicine composition for treating neurosis | |
| CN1150928C (en) | Medicine for curing cancers and its preparation method | |
| CN102940785B (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN105311219A (en) | Health Jieyu Ningshen mixture | |
| CN109985209A (en) | A kind of Chinese medicine composition and its preparation method and application for treating advanced gastric carcinoma | |
| CN101919986B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
| CN109045191B (en) | Traditional Chinese medicine composition for treating intermenstrual bleeding diseases and application thereof | |
| CN101628104B (en) | Traditional Chinese medicine composition used for treating melancholia | |
| CN102327587B (en) | Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation | |
| CN103301211A (en) | Traditional Chinese medicine for treating leukopenia | |
| CN102973872A (en) | Hepatitis B treatment drug | |
| CN101450161B (en) | Traditional Chinese medicine formula for treating vascular headache | |
| CN106362092A (en) | Qi supplementing and blood circulation activating traditional Chinese medicine composition for treating liver fibrosis | |
| CN104707011B (en) | Treat herbal mixture and the application of Sjogren syndrome | |
| CN102283993B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN104147419A (en) | Traditional Chinese medicine composition for treating immune thrombocytopenia | |
| CN105250754B (en) | It is a kind of alleviate menopause symptom Chinese medicine composition and its application | |
| CN104940516A (en) | Traditional Chinese medicine composition for treating chronic aplastic anemia, and preparation method and application thereof | |
| CN103830684B (en) | One treats menorrheal pharmaceutical composition and application thereof | |
| CN108553611A (en) | A kind of antifatigue anti senility, the natural herb health tea for preventing inferior health | |
| CN103495108A (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN103263580A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103263595A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103006826B (en) | Chinese medicinal compound for treating insomnia in female climacteric | |
| CN106511886A (en) | Traditional Chinese medicinal preparation for treating sjogren's syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |